You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

TRIAMCINOLONE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Triamcinolone patents expire, and when can generic versions of Triamcinolone launch?

Triamcinolone is a drug marketed by Barr, Impax Labs, Ivax Sub Teva Pharms, Mylan, Purepac Pharm, Roxane, Sandoz, Teva, Watson Labs, Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Chartwell Rx, Cosette, Encube, Fougera Pharms, Glenmark Pharms Ltd, Macleods Pharms Ltd, Micro Labs, Morton Grove, Norvium Bioscience, Padagis Us, Pharmaderm, Pharmafair, Strides Pharma, Taro, Topiderm, Amneal, Eugia Pharma, Long Grove Pharms, Mylan Labs Ltd, Parnell, Teva Pharms Usa, Epic Pharma Llc, Pai Holdings Pharm, Quagen, Wockhardt Bio Ag, Aurobindo Pharma Ltd, Cintex Svcs, Glenmark Speclt, Padagis Israel, Rising, Sciegen Pharms Inc, Apotex, and Perrigo Pharma Intl. and is included in one hundred and fourteen NDAs.

The generic ingredient in TRIAMCINOLONE is triamcinolone diacetate. There are fifty-one drug master file entries for this compound. Additional details are available on the triamcinolone diacetate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TRIAMCINOLONE?
  • What are the global sales for TRIAMCINOLONE?
  • What is Average Wholesale Price for TRIAMCINOLONE?
Drug patent expirations by year for TRIAMCINOLONE
Drug Prices for TRIAMCINOLONE

See drug prices for TRIAMCINOLONE

Drug Sales Revenue Trends for TRIAMCINOLONE

See drug sales revenues for TRIAMCINOLONE

Recent Clinical Trials for TRIAMCINOLONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
David SheynPhase 2/Phase 3
Ain Shams UniversityPhase 3
Tanta UniversityN/A

See all TRIAMCINOLONE clinical trials

Medical Subject Heading (MeSH) Categories for TRIAMCINOLONE

US Patents and Regulatory Information for TRIAMCINOLONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa TRIAMCINOLONE ACETONIDE triamcinolone acetonide INJECTABLE;INJECTION 209852-001 Oct 5, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fougera Pharms TRIAMCINOLONE ACETONIDE triamcinolone acetonide OINTMENT;TOPICAL 085691-003 Approved Prior to Jan 1, 1982 AT RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Morton Grove TRIAMCINOLONE ACETONIDE triamcinolone acetonide CREAM;TOPICAL 088095-001 Sep 1, 1983 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fougera Pharms TRIAMCINOLONE ACETONIDE triamcinolone acetonide CREAM;TOPICAL 085692-003 Approved Prior to Jan 1, 1982 AT RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.